Horizon Pharma plc Announces DUEXIS(R) Selected as Winner

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award

CHICAGO, IL--(Marketwired - Oct 31, 2014) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that DUEXIS ® (ibuprofen/famotidine) has been selected as one of the winners of the 13th annual Chicago Innovation Awards . Last night at Chicago's Harris Theater, Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, received the award with nearly 1,500 business and civic leaders in attendance. The Chicago Innovation Awards, celebrating its 13 th year, recognizes the most innovative new products or services brought to market or to public service each year. 

"With a large percentage of the approximately 50 million individuals suffering from arthritis in the United States taking prescription-strength nonsteroidal anti-inflammatory drugs, or NSAIDs, and therefore at risk of developing gastrointestinal (GI) ulcers, Horizon Pharma developed DUEXIS, an innovative combination of ibuprofen and famotidine, that reduces pain and inflammation while reducing the risk of developing GI ulcers," said Tom Kuczmarski, co-founder of the Chicago Innovation Awards. "Horizon Pharma's product DUEXIS shows how innovation can be simple and clever yet profoundly impactful."

For the first time in the NSAID market, Horizon Pharma developed a product-DUEXIS-that combined prescription-strength ibuprofen with high-dose famotidine to address pain and inflammation associated with osteoarthritis (OA) and rheumatoid arthritis (RA) and to reduce the development of GI ulcers due to the NSAID component ibuprofen. Ibuprofen is the most prescribed NSAID in the United States. By combining high-dose prescription-strength famotidine along with prescription strength ibuprofen in one tablet, Horizon Pharma has enabled patients to reduce their arthritis pain and inflammation while reducing the risk of developing GI ulcers associated with taking ibuprofen alone. 

"On behalf of my colleagues at Horizon Pharma, I am honored to receive the Chicago Innovation Award for our work with DUEXIS," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "Our focus is to improve patients' lives by commercializing products that address unmet needs and DUEXIS was the first product we introduced. We are thrilled to be recognized for our work in helping individuals living with OA and RA to better manage their pain and inflammation while reducing their risk of developing GI ulcers."

About DUEXIS

DUEXIS, a proprietary single-tablet combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months. For more information, please visit  www.DUEXIS.com .

The following details are from the DUEXIS (ibuprofen and famotidine) Prescribing Information. For more information, please see the Medication Guide and the full Prescribing Information for DUEXIS available at www.DUEXIS.com . Always talk with your health care provider if you have questions.

Approved Uses for DUEXIS

DUEXIS, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.

Important Safety Information

  • Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, a component of DUEXIS, may increase the chance of a heart attack or stroke, which can be fatal. This chance increases with longer use and in people who have heart disease or risk factors for heart disease
  • DUEXIS should not be used before or after a type of heart surgery called coronary artery bypass graft (CABG)
  • NSAID-containing medications like DUEXIS may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer. These problems can happen without warning and can lead to death. Older patients may have a greater chance of developing these problems

DUEXIS is not right for everyone. People who have had asthma, hives or an allergic reaction to aspirin or other NSAIDs should not take DUEXIS. Women in the late stages of pregnancy should not take DUEXIS. People who have had allergic reactions to medications like famotidine (histamine H 2 -receptor antagonists) should not take DUEXIS.

Tell your health care provider right away if you have signs of active bleeding (persistent and unexplained) while you are taking DUEXIS.

NSAID-containing medications like DUEXIS can cause high blood pressure or make existing high blood pressure worse, either of which can increase the chance of a heart attack or stroke. Your health care provider should check your blood pressure while you are taking DUEXIS.

Before you start taking DUEXIS, tell your health care provider if you have heart problems, kidney problems or liver problems or if you are taking medications for high blood pressure. DUEXIS can increase the chance of potentially significant liver injury and/or kidney injury, which may be fatal. Stop taking DUEXIS immediately and contact your health care provider if you experience any signs and/or symptoms of liver or kidney injury.

Serious allergic reactions, including skin reactions, can happen without warning and can be life threatening. Stop taking DUEXIS and consult your doctor immediately if you get a skin rash or if you start to have problems breathing or swallowing, or if you develop swelling of your face or throat.

The most common side effects of DUEXIS include nausea, diarrhea, constipation, upper abdominal pain and headache.

About Horizon Pharma plc

Horizon Pharma plc (NASDAQ: HZNP) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE ® (interferon gamma-1b), DUEXIS ® (ibuprofen/famotidine), RAYOS ®  (prednisone) delayed-release tablets and VIMOVO ® (naproxen/esomeprazole). Beginning in January 2015, the Company will also begin marketing PENNSAID ® (diclofenac sodium topical solution) 2% w/w in the U.S. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com .

Media and Investor Contact: Elizabeth M. Higashi, CFA Vice President, Investor Relations Email Contact +1 224 383-3285

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 56

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 63

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 234

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 11

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 53

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading

Top 5 Most Recently Viewed Articles

FlexShopper Partners with PayPossible to Enhance Payment Solutions

Updated Category News Views 152

FlexShopper Enhances Consumer Payment Solutions FlexShopper Inc., a leading name in lease-to-own (LTO) retail and payment solutions, is thrilled to share the news of its strategic partnership with PayPossible. This collaboration focuses on expanding flexible financing options for consumers through the integration of FlexShopper’s services into PayPossible’s renowned...

Continue Reading
SanDisk Set to Thrive Amid Rising AI Demand and Supply Gaps

Updated Category News Views 356

SanDisk Corporation and the Promise of AI Demand SanDisk Corporation (NASDAQ: SNDK) is experiencing a wave of investor optimism as shares surged recently. This positive sentiment primarily stems from the anticipated growth in the NAND flash memory market, driven by increasing demand from AI data centers and limited supply conditions. Market Dynamics and Future Performance...

Continue Reading
Exciting Preparations for FIFA World Cup 26 in Miami

Updated Category News Views 437

Countdown to FIFA World Cup 26 in Miami Greater Miami and Miami Beach: A Hub for Global Sports As we approach a thrilling year leading up to the FIFA World Cup 26™, anticipation builds across Greater Miami. Miami is set to solidify its status as a global sports capital, ready to host seven electrifying matches at the Hard Rock Stadium. The preparations are underway for...

Continue Reading
JKB and IFC's Bold Green Bond Move Spurs Finance

Updated Category News Views 22

Amman Sets the Stage for Green Finance Watch out, folks! Jordan Kuwait Bank (JKB), teaming up with the International Finance Corporation (IFC), is stirring the pot in Amman with its second Green Bond. This is no small fry—it’s a big-time financial ballet with a USD 100 million investment aimed squarely at reshaping the landscape of sustainable finance in Jordan....

Continue Reading
Discover Modern Living at Modera St. Paul in Dallas

Updated Category News Views 194

Modera St. Paul Opens Doors to New Residents Mill Creek Residential has recently welcomed its first residents to Modera St. Paul, a striking mixed-use community positioned in the heart of Dallas. This development adds a total of 333 homes alongside street-level retail space, creating a vibrant urban living experience. A Prime Location for Modern Living Situated at a key...

Continue Reading